Categories Technology

Elon Musk might sell his Tesla stock to fund space travel in the future

Tesla chief Elon Musk says that in about 20 years, he plans to sell a ‘major’ stake in Tesla to finance the Mars colonization plans by SpaceX. The CEO of two billion-dollar companies – Tesla and SpaceX – took to Twitter to announce this.

Earlier, Musk wanted to leave Tesla’s head role to focus on SpaceX.

Even though it was said to come to pass when Model 3 achieves volume production, the billionaire seemed to have ramped up his involvement in the electric car maker. But his aim looks to be the same – to benefit SpaceX.

Tesla vehicle production and deliveries

According to the new CEO compensation plan at Tesla (TSLA), Musk looks to receive a multi-billion dollar payout. While it would significantly spike his already substantial stake in the automaker, Elon plans to drive it all back to his love for space.

The CEO on Friday tweeted his long-term plan – just like his 2016 sale of about 2.8 million Tesla shares to pay taxes and donate to charity – he would sell a huge chunk in about twenty years and use it to aid space exploration efforts in SpaceX.

 

 


While selling shares is almost always a red signal in the Street, the eccentric billionaire’s explanation for a stock sale twenty years into the future seem to have mitigated that. One more feather in the cap of norm-defying Musk.

Related: How Elon Musk tweaked the system with Tesla

In the said timeline of two decades, it is hoped that Tesla would achieve a sort-of stable and good position in the market for Musk’s stake sale to have much effect. Meanwhile, the prospects of space travel into the future looks more and more achievable. It looks like Musk has it all sorted out. Or is he just bluffing?

Related: Elon Musk admits to Tesla Model 3 braking issue, confirms firmware fix
Related: Elon Musk increases his stake in Tesla; buys 72,500 shares

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top